Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 20;403(10423):305-324.
doi: 10.1016/S0140-6736(23)01429-0.

Medical, surgical, and physical treatments for Parkinson's disease

Affiliations
Review

Medical, surgical, and physical treatments for Parkinson's disease

Tom Foltynie et al. Lancet. .

Abstract

Although dopamine replacement therapy remains a core component of Parkinson's disease treatment, the onset of motor fluctuations and dyskinetic movements might require a range of medical and surgical approaches from a multidisciplinary team, and important new approaches in the delivery of dopamine replacement are becoming available. The more challenging, wide range of non-motor symptoms can also have a major impact on the quality of life of a patient with Parkinson's disease, and requires careful multidisciplinary management using evidence-based knowledge, as well as appropriately tailored strategies according to the individual patient's needs. Disease-modifying therapies are urgently needed to prevent the development of the most disabling refractory symptoms, including gait and balance difficulties, cognitive impairment and dementia, and speech and swallowing impairments. In the third paper in this Series, we present the latest evidence supporting the optimal treatment of Parkinson's disease, and describe an expert approach to many aspects of treatment choice where an evidence base is insufficient.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests TF has received grants from Edmond J Safra Foundation, National Institute of Health Research, Michael J Fox Foundation for Parkinson's Research, John Black Charitable Foundation, Cure Parkinson's Trust, Innovate UK, Van Andel Research Institute, and Defeat Multiple System Atrophy Alliance. He has served on advisory boards for Voyager Therapeutics, Handl Therapeutics, Living Cell Technologies, Bial, Profie Pharma, and Peptron. He has received honoraria for talks sponsored by Bial, Profile Pharma, Boston Scientific, and Novo Nordisk. VB has received grants from Alberta Health, Allergan, Paladin Labs, and Ipsen. She has served on an advisory board for Biogen, received honoraria from the International Parkinson and Movement Disorder Society, and is a site principal investigator for Biogen. SF has received clinic support from the Edmond J Safra Foundation for Parkinson Research, Parkinson Foundation, and the Toronto Western and General Foundation; has received research funding from the Michael J Fox Foundation for Parkinson's Research, National Institutes of Health (Dystonia Coalition), and Parkinson Canada; has received honoraria from the International Parkinson and Movement Disorder Society; is a site principal investigator for clinical trials for Alexion, Biotie, Eisai, Pharma2B, and Revance; has received consultancy and speaker fees from Alexio, Bial, Pharma 2B, Sunovion, and Paladin; and has received royalties from Oxford University Press. AAK has received grants from Deutsche Forschungsgemeinschaft, German Federal Ministry of Education and Research, and Lundbeck Foundation. She has served on advisory boards for Medtronic and Boston Scientific; and has received honoraria for talks sponsored by Medtronic, Boston Scientific, Ipsen, and Teva. She is supported by the Deutsche Forschungsgemeinschaft (project ID 424778381–TRR 295). AJL has consultancy agreements with Bial and Britannia Pharmaceuticals. FL declares no competing interests.

Publication types

LinkOut - more resources